June 4, 2018 Adjuvant chemotherapy with a modified FOLFIRINOX (mFOLFIRINOX) regimen was superior to gemcitabine with regard to disease-free, metastasis-free, and overall survival (OS) in patients with resected pancreatic cancer, according to a new randomized phase III trial. The regimen should now be considered the standard of care in this setting. Six months of...
Pro zobrazení tohoto obsahu je třeba být přihlášen.